Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | FASN | P49327 | 1/20 | 1.00 |
| ▸ | KAT2A | Q92830 | 3/20 | 0.77 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7913812 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| (+/-)-Protolichesterinic Acid SCHEMBL7913885 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL2993206 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL6428925 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL7920753 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL7913816 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL7920321 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| SCHEMBL3007085 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| Protolichesterinic Acid SCHEMBL7913878 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA | |
| Protolichesterinic Acid SCHEMBL7913888 | 1.00 | POLB (1.00) | POLBFASNKAT2ADAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137934-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-05-13 | — | — | US | claimed |
| US-10272088-B2 | FAS inhibitors and methods associated therewith | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2019-04-30 | — | — | US | claimed |
| EP-3458448-A1 | METHODS OF USING FASN INHIBITORS | Forma Therapeutics, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| WO-2018170316-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-09-20 | — | — | WO | claimed |
| US-20170360789-A1 | FAS Inhibitors and Methods Associated Therewith | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2017-12-21 | — | — | US | claimed |
| WO-2017189613-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-11-02 | — | — | US | claimed |
| US-20170268027-A1 | METHOD FOR SYNTHESIS OF FATTY ACIDS | FIDOP (FONDS DE DEVELOPPEMENT DES FILIERES DES OLEAGINEUX ET DES PROTEAGINEUX) (FR) | 2017-09-21 | — | — | US | claimed |
| US-20170202982-A1 | Hyaluronic Acid-Based Nanoparticles as Biosensors for Imaging-Guided Surgery and Drug Delivery Vehicles and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-07-20 | — | — | US | claimed |
| WO-2016076924-A2 | FAS INHIBITORS AND METHODS ASSOCIATED THEREWITH | WAKE FOREST UNIVERSITY (US) | 2016-05-19 | — | — | WO | claimed |
| WO-2016011436-A1 | HYALURONIC ACID-BASED NANOPARTICLES AS BIOSENSORS FOR IMAGING-GUIDED SURGERY AND DRUG DELIVERY VEHICLES AND METHODS ASSOCIATED THEREWITH | WAKE FOREST UNIVERSITY (US) | 2016-01-21 | — | — | WO | claimed |
| WO-2013155528-A2 | METHODS FOR REDUCING BRAIN INFLAMMATION, INCREASING INSULIN SENSITIVITY, AND REDUCING CERAMIDE LEVELS | FASGEN, INC. (US) | 2013-10-17 | — | — | WO | claimed |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009151910-A2 | COMBINATION PRODUCT OF RECEPTOR TYROSINE KINASE INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR FOR TREATING CANCER | WYETH (US) | 2009-12-17 | — | — | WO | claimed |
| EP-1565180-A4 | A METHOD FOR INHIBITING CANCER DEVELOPMENT BY FATTY ACID SYNTHASE INHIBITORS | FASGEN LLC (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070142456-A1 | Method for inhibiting cancer development by fatty acid synthase inhibitors | FASGEN, LLC (US) | 2007-06-21 | — | — | US | claimed |
| EP-1565180-A2 | A METHOD FOR INHIBITING CANCER DEVELOPMENT BY FATTY ACID SYNTHASE INHIBITORS | Fasgen, LLC (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004041189-A2 | A METHOD FOR INHIBITING CANCER DEVELOPMENT BY FATTY ACID SYNTHASE INHIBITORS | FASGEN LLC (US) | 2004-05-21 | — | — | WO | claimed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | disclosed |
| WO-1997018806-A1 | INHIBITION OF FATTY ACID SYNTHASE AS A MEANS TO REDUCE ADIPOCYTE MASS | THE JOHNS HOPKINS UNIVERSITY (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202982-A1 | Hyaluronic Acid-Based Nanoparticles as Biosensors for Imaging-Guided Surgery and Drug Delivery Vehicles and Methods Associated Therewith | CD44, HLA-A, HLA-C | POLB 3593/4885FASN 1177/4885KAT2A 1714/4885 |
| US-20170312273-A1 | METHODS OF USING FASN INHIBITORS | FASN, IL1RN, CCR1 | POLB 2387/4885FASN 1/4885KAT2A 1651/4885 |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | POLB 2213/4885FASN 1/4885KAT2A 2895/4885 |
| US-20070142456-A1 | Method for inhibiting cancer development by fatty acid synthase inhibitors | FASN, SCD, FADS2 | POLB 702/4885FASN 1/4885KAT2A 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.